Item 8.01 Other Events.
On March 28, 2023, Anebulo Pharmaceuticals, Inc. filed a Current Report on Form
8-K (the "March 8-K") that included results from its randomized, double-blind,
placebo-controlled Phase 2 clinical trial evaluating ANEB-001 as a potential
treatment for ACI in healthy volunteers challenged with oral
delta-9-tetrahydrocannabinol. The charts contained in Exhibit 99.1 to this
Current Report on Form 8-K are incorporated by reference herein and graphically
present data that is consistent with the data reported in the March 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
99.1 Part B Final Data Charts
104 Cover Page of Interactive Data File (embedded within the Inline XBRL
document).
© Edgar Online, source Glimpses